- Home
- VRTS vs GERN Comparison
VRTS vs GERN Comparison
Compare VRTS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTS
- GERN
- Stock Information
- Founded
- VRTS 1988
- GERN 1990
- Country
- VRTS United States
- GERN United States
- Employees
- VRTS N/A
- GERN N/A
- Industry
- VRTS Investment Managers
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- VRTS Finance
- GERN Health Care
- Exchange
- VRTS Nasdaq
- GERN Nasdaq
- Market Cap
- VRTS 1.3B
- GERN 1.5B
- IPO Year
- VRTS 1992
- GERN 1996
- Fundamental
- Price
- VRTS $173.79
- GERN $1.48
- Analyst Decision
- VRTS Hold
- GERN Buy
- Analyst Count
- VRTS 4
- GERN 11
- Target Price
- VRTS $225.75
- GERN $5.80
- AVG Volume (30 Days)
- VRTS 47.7K
- GERN 15.1M
- Earning Date
- VRTS 04-25-2025
- GERN 05-01-2025
- Dividend Yield
- VRTS 5.17%
- GERN N/A
- EPS Growth
- VRTS N/A
- GERN N/A
- EPS
- VRTS 16.89
- GERN N/A
- Revenue
- VRTS $906,949,000.00
- GERN $76,994,000.00
- Revenue This Year
- VRTS N/A
- GERN $208.83
- Revenue Next Year
- VRTS $3.20
- GERN $57.49
- P/E Ratio
- VRTS $10.30
- GERN N/A
- Revenue Growth
- VRTS 7.30
- GERN 32386.92
- 52 Week Low
- VRTS $167.13
- GERN $1.46
- 52 Week High
- VRTS $252.82
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- VRTS 41.72
- GERN 28.23
- Support Level
- VRTS $169.00
- GERN $1.63
- Resistance Level
- VRTS $180.92
- GERN $1.89
- Average True Range (ATR)
- VRTS 4.89
- GERN 0.11
- MACD
- VRTS 0.59
- GERN 0.02
- Stochastic Oscillator
- VRTS 48.30
- GERN 6.82
About VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to individuals and institutions. Its retail products include open-end mutual funds, closed-end funds, exchange-traded funds, and variable insurance funds. Geographically, the activities are carried out through the region of the U.S. and the group generates revenue through investment management fees, distribution and service fees and administration and shareholder service fees.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.